CMV Immunity Monitoring in Lung Transplant Recipients

Launched by NYU LANGONE HEALTH · Jan 24, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new way to manage antiviral medication after lung transplants. It aims to see if a special lab test, called the inSIGHT™ CMV T Cell Immunity Panel, can help doctors decide how long patients should take a medication called valganciclovir. This medication is used to prevent infections from a common virus called cytomegalovirus (CMV), which can be a concern for people who have had a transplant. By using this test, the goal is to safely reduce the time patients need to take the medication, potentially improving their quality of life.

To participate in this study, individuals must have received a lung transplant or a multi-organ transplant that includes a lung at NYU Langone Health, and they must show some level of immunity to CMV. Participants should be between the ages of 65 and 74. They will need to agree to participate and provide informed consent. It's important to note that individuals who have received specific types of immunosuppressive treatments, or who are pregnant or breastfeeding, cannot take part in the study. Participants can expect to undergo the lab test to help guide their medication plan while being closely monitored for safety throughout the trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Received a lung transplant, or multi-organ transplant involving a lung at NYU Langone Health
• • 2. Pre-existing serological immunity to CMV (R+)
• • 3. Able and willing to provide informed consent
• Exclusion Criteria:
• • 1. Anti-thymocyte globulin induction immunosuppression
• • 2. Perioperative desensitization
• • 3. Pregnant or breastfeeding women